Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Forma Therapeutics was a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. Its primary focus was on sickle cell disease (SCD), with its lead candidate etavopivat, and other rare blood disorders. In October 2022, Forma Therapeutics was acquired by Novo Nordisk, integrating its innovative pipeline and expertise into Novo Nordisk's broader rare disease portfolio to accelerate therapeutic advancements for patients.
The Watertown headquarters served as the central nexus for Forma's research and development activities, clinical trial operations, and corporate administration, spearheading the company's mission to create treatments for rare hematologic conditions and cancers.
Located in 'The Arsenal on the Charles,' a redeveloped historic arsenal complex, the facility featured modern laboratory spaces tailored for drug discovery and research, alongside collaborative office environments designed to foster innovation and teamwork.
As a clinical-stage biopharmaceutical entity, Forma Therapeutics cultivated a dynamic, science-centric, and patient-oriented work culture. This environment emphasized intensive collaboration, pioneering innovation, and a steadfast commitment to addressing unmet medical needs in rare diseases, typical of a fast-paced drug development setting.
The Watertown location was strategically important due to its immersion in the Greater Boston area, a globally recognized cluster of leading academic institutions, cutting-edge research organizations, and numerous biotech and pharmaceutical companies. This proximity facilitated talent acquisition, scientific collaboration, and industry partnerships.
Prior to its acquisition by Novo Nordisk, Forma Therapeutics' global footprint was primarily characterized by its international clinical trial operations and strategic collaborations. While its physical R&D and corporate offices were U.S.-based in Watertown, MA, the company managed and conducted clinical studies for its drug candidates, such as etavopivat for sickle cell disease, across multiple countries. This involved extensive engagement with clinical research organizations (CROs), medical investigators, and patient advocacy groups worldwide to advance its therapeutic programs. Additionally, its business development and scientific outreach activities involved interactions with potential partners, academic institutions, and stakeholders on a global scale.
500 Arsenal Street, Suite 100
Watertown
MA
USA
Address: Operations were largely centralized at the 500 Arsenal Street, Watertown, MA headquarters. Historically, Forma had other research sites (e.g., Branford, CT), but these were consolidated over time to enhance focus and collaboration at the main facility leading up to its acquisition by Novo Nordisk.
To streamline operations and foster a cohesive R&D and corporate environment within the strategic Greater Boston biotech ecosystem, ensuring focused efforts on its therapeutic pipeline.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Forma Therapeutics' leadership includes:
Forma Therapeutics has been backed by several prominent investors over the years, including:
In the period leading up to its acquisition by Novo Nordisk in late 2022, Forma Therapeutics experienced notable executive transitions, particularly within its finance leadership. Following the completion of the acquisition, the existing executive team structure of Forma Therapeutics was integrated into Novo Nordisk's organization or individuals transitioned out of their roles as the company became part of Novo Nordisk.
Discover the tools Forma Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Novo Nordisk, Forma Therapeutics likely utilized common corporate email address formats based on employee names and its domain `formatherapeutics.com`. Standard patterns for biopharmaceutical companies include combinations of first name, last name, and initials. Post-acquisition, official communications would transition to Novo Nordisk's email systems, and the `formatherapeutics.com` domain may no longer be active for email correspondence.
Commonly, formats like `[first_initial][last]@formatherapeutics.com` (e.g., jsmith@formatherapeutics.com) or `[first].[last]@formatherapeutics.com` (e.g., john.smith@formatherapeutics.com) were probable. Example: flast@formatherapeutics.com
Format
jsmith@formatherapeutics.com
Example
70 (Historically; domain likely inactive or communications redirected post-acquisition)%
Success rate
Novo Nordisk • October 17, 2022
Novo Nordisk announced the successful completion of its acquisition of Forma Therapeutics, Holdings Inc. (Forma). The acquisition, including its lead development candidate etavopivat for sickle cell disease (SCD), aligns with Novo Nordisk’s strategy to enhance its presence in SCD and rare blood disorders....more
Business Wire • September 1, 2022
Novo Nordisk and Forma Therapeutics announced a definitive agreement for Novo Nordisk to acquire Forma Therapeutics for $20 per share in cash, representing a total equity value of $1.1 billion. The transaction aimed to leverage Novo Nordisk's expertise to advance Forma's SCD program....more
Business Wire • June 12, 2022
Forma Therapeutics shared updated results from its Phase 1 clinical trial of etavopivat in patients with sickle cell disease (SCD) at the European Hematology Association (EHA) 2022 Congress. The data indicated etavopivat was generally well tolerated and showed positive effects on anemia and red blood cell health markers....more
GlobeNewswire • June 19, 2020
Forma Therapeutics announced the pricing of its initial public offering (IPO) of 13,882,352 shares of common stock at $17.00 per share, for gross proceeds of approximately $236.0 million. The company's shares began trading on the Nasdaq Global Select Market under the ticker 'FMTX'....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Forma Therapeutics, are just a search away.